Changes in anticancer treatment plans in patients with solid cancer hospitalized with COVID-19: analysis of the nationwide BSMO-COVID registry providing lessons for the future

Resource allocation during the coronavirus disease 2019 pandemic and the impact on patients with lung cancer: a systematic review

“…In a retrospective, study consisting of 928 patients at 19 different hospitals across Belgium, there was a trend towards higher mortality in patients with lung cancer as compared to other solid organ cancers (27.6% vs 20.8%, P = 0.062) [ 45 ].…”

“…These differences in findings are likely multifactorial including the fact that many of these studies were published in different regions of the world where the impact and timing of the various waves of the pandemic differed, there were differing responses to the pandemic from governments and healthcare authorities, and there are diverse healthcare systems with contrasting priorities and resource utilization. Among patients undergoing surgical intervention for lung cancers during the pandemic, there were few differences identified in postoperative outcomes [ 18 , 19 , 21 , 25 , 28 , 40–42 , 45 , 46 ]. Finally, when accounting for the above disruptions in screening, assessments, diagnostics and interventions, studies aimed at modelling the impact of these changes predict significant increases in mortality for patients with lung cancer in the years to come [ 47–50 ].…”

COVID-19 in cancer patients: update from the joint analysis of the ESMO-CoCARE, BSMO, and PSMO international databases

“…As the pandemic has progressed, the availability of effective vaccines and therapeutics as well as the development of new variants could influence the severity of COVID-19 in cancer patients, hence we proceeded to the second analysis of ESMO CoCARE data, jointly with BSMO’s (Belgian Society of Medical Oncology)( 19 ) and PSMO’s (Portuguese Society of Medical Oncology) registries. Herein, we report on the results of this updated analysis, which aimed at assessing significant prognostic factors for the COVID-19 outcomes of hospitalization, mortality, Intensive Care Unit (ICU) admission, and overall survival (OS).…”

Learning lessons from the COVID-19 pandemic for real-world evidence research in oncology—shared perspectives from international consortia

“…These aimed to understand features and factors associated with COVID-19 overall mortality and severity in patients with cancer, optimal management and the impact of the infection in terms of cancer care delivery. 1 , 2 , 3 , 4 , 5 , 6 , 7 This collaborative process was conducted at high speed, with several adjustments required over time as new data, questions and challenges emerged, such as disruptions in the health care systems and patient care globally, new virus strains/variants, COVID-19 treatments and vaccination, and the demonstration of long-term effects of the infection.…”